Tango Therapeutics, Inc. - 10-Q Filing
Tango Therapeutics reports Q3 2026 financial results including collaboration revenue from Gilead agreement and ongoing R&D expenditures.
Tickers: $TNGX
Read the full article at SEC EDGAR
Part of the story bioAffinity Technologies, Inc. - 10-Q Filing (3 articles)